Teva Brings In Ranibizumab Biosimilar As Bioeq Files In Europe
Israeli Firm Announces Broader Commercialization Agreement For Lucentis Rival
Biosimilar Lucentis in Europe is once again in the headlines, as Teva announced a deal to in-license Bioeq and Formycon’s FYB201 ranibizumab candidate in several key global markets.
You may also be interested in...
Bioeq’s Ranivisio ranibizumab biosimilar has gained European Commission authorization for all innovator indications including wet AMD, the leading cause of blindness among over-65s.
Formycon has seen its FYB201 ranibizumab biosimilar rival to Lucentis recommended for approval by the EMA’s CHMP, under the name Ranivisio. Teva has rights to market the product in Europe and is preparing for launch.
Teva is gearing up to introduce the Ongavia ranibizumab biosimilar in the UK, following an approval by the local regulator ahead of its European counterpart. The development means the Israeli firm and partners Bioeq and Formycon could secure a global first launch of a rival to Lucentis, ahead of expected imminent launches by Samsung Bioepis of its Byooviz version in the US and Europe.